A citation-based method for searching scientific literature

Carol A Christianson, Kirsty M McWalter, Nancy Steinberg Warren. J Allied Health 2005
Times Cited: 6







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The gap between practice and genetics education of health professionals: HuGEM survey results.
E V Lapham, C Kozma, J O Weiss, J L Benkendorf, M A Wilson. Genet Med 2000
42
50

Polymorphic hydroxylation of perhexiline maleate in man.
R G Cooper, D A Evans, E J Whibley. J Med Genet 1984
58
16

Impaired oxidation of debrisoquine in patients with perhexiline liver injury.
M Y Morgan, R Reshef, R R Shah, N S Oates, R L Smith, S Sherlock. Gut 1984
147
16

Is perhexiline essential for the optimal management of angina pectoris?
J D Horowitz, I K Button, L Wing. Aust N Z J Med 1995
21
16

Pharmacogenetics in drug regulation: promise, potential and pitfalls.
Rashmi R Shah. Philos Trans R Soc Lond B Biol Sci 2005
43
16

Pharmacogenetics of antihypertensive drug responses.
Gary L Schwartz, Stephen T Turner. Am J Pharmacogenomics 2004
33
16


Polymorphic hydroxylation of perhexiline in vitro.
L B Sørensen, R N Sørensen, J O Miners, A A Somogyi, N Grgurinovich, D J Birkett. Br J Clin Pharmacol 2003
28
16

Pharmacogenomics and acquired long QT syndrome.
Jeroen Aerssens, Aimée D C Paulussen. Pharmacogenomics 2005
24
16


The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome.
G M Vincent, K W Timothy, M Leppert, M Keating. N Engl J Med 1992
493
16

Changes in prescribed drug doses after market introduction.
Eibert R Heerdink, John Urquhart, Hubert G Leufkens. Pharmacoepidemiol Drug Saf 2002
43
16

Gemfibrozil greatly increases plasma concentrations of cerivastatin.
Janne T Backman, Carl Kyrklund, Mikko Neuvonen, Pertti J Neuvonen. Clin Pharmacol Ther 2002
254
16

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
Laurent Bodin, Céline Verstuyft, David-Alexandre Tregouet, Annie Robert, Liliane Dubert, Christian Funck-Brentano, Patrice Jaillon, Philippe Beaune, Pierre Laurent-Puig, Laurent Becquemont,[...]. Blood 2005
286
16

Genetic knowledge and counselling skills of Dutch cardiologists: sufficient for the genomics era?
I M van Langen, E Birnie, N J Leschot, G J Bonsel, A A M Wilde. Eur Heart J 2003
35
16

Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
Benedetta C Sallustio, Ian S Westley, Raymond G Morris. Br J Clin Pharmacol 2002
42
16

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.
Yi-Shin Huang, Herng-Der Chern, Wei-Juin Su, Jaw-Ching Wu, Shi-Chuan Chang, Chi-Huei Chiang, Full-Young Chang, Shou-Dong Lee. Hepatology 2003
271
16

QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.
Adrián LLerena, Roland Berecz, Alfredo de la Rubia, Pedro Dorado. J Psychopharmacol 2002
47
16



Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
James Cross, Howard Lee, Agnes Westelinck, Julie Nelson, Charles Grudzinskas, Carl Peck. Pharmacoepidemiol Drug Saf 2002
86
16

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Jennie T Chang, Judy A Staffa, Mary Parks, Lanh Green. Pharmacoepidemiol Drug Saf 2004
107
16


Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.
Arlene R Hughes, Michael Mosteller, Aruna T Bansal, Kirstie Davies, Stephen A Haneline, Eric H Lai, Keith Nangle, Trevor Scott, William R Spreen, Liling L Warren,[...]. Pharmacogenomics 2004
177
16


A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin.
Chikako Ishikawa, Hiroshi Ozaki, Toshiaki Nakajima, Toshihiro Ishii, Saburo Kanai, Saeko Anjo, Kohji Shirai, Ituro Inoue. J Hum Genet 2004
45
16

Measuring the value of pharmacogenomics.
Kathryn A Phillips, Stephanie L Van Bebber. Nat Rev Drug Discov 2005
70
16


Pharmacogenetics in clinical practice: considerations for testing.
Simon Constable, Michael R Johnson, Munir Pirmohamed. Expert Rev Mol Diagn 2006
10
16

UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Leslie E Carlini, Neal J Meropol, John Bever, Michael L Andria, Todd Hill, Philip Gold, Andre Rogatko, Hao Wang, Rebecca L Blanchard. Clin Cancer Res 2005
193
16

Low penetrance in the long-QT syndrome: clinical impact.
S G Priori, C Napolitano, P J Schwartz. Circulation 1999
561
16


Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
Sally Inglis, Simon Stewart. Eur J Cardiovasc Nurs 2006
18
16


Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.
Annalise M Martin, David Nolan, Silvana Gaudieri, Coral Ann Almeida, Richard Nolan, Ian James, Filipa Carvalho, Elizabeth Phillips, Frank T Christiansen, Anthony W Purcell,[...]. Proc Natl Acad Sci U S A 2004
326
16

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
S Mallal, D Nolan, C Witt, G Masel, A M Martin, C Moore, D Sayer, A Castley, C Mamotte, D Maxwell,[...]. Lancet 2002
917
16

The role of metabolic activation in drug-induced hepatotoxicity.
B Kevin Park, Neil R Kitteringham, James L Maggs, Munir Pirmohamed, Dominic P Williams. Annu Rev Pharmacol Toxicol 2005
281
16


Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?
Julia Kirchheiner, Uwe Fuhr, Jürgen Brockmöller. Nat Rev Drug Discov 2005
101
16

Clinical pharmacokinetics of atomoxetine.
John-Michael Sauer, Barbara J Ring, Jennifer W Witcher. Clin Pharmacokinet 2005
136
16

Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes.
Zhuoqian Sun, Patrice M Milos, John F Thompson, David B Lloyd, Amy Mank-Seymour, Jodi Richmond, Jason S Cordes, Jun Zhou. J Mol Cell Cardiol 2004
43
16

Food-drug interactions.
Lars E Schmidt, Kim Dalhoff. Drugs 2002
170
16

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.
D Dai, D C Zeldin, J A Blaisdell, B Chanas, S J Coulter, B I Ghanayem, J A Goldstein. Pharmacogenetics 2001
372
16

Perhexiline maleate-associated hepatic injury prevalence and characteristics.
R Poupon, L Rosensztajn, P Prudhomme de Saint-Maur, A Lageron, T Gombeau, F Darnis. Digestion 1980
20
16

The significance of QT interval in drug development.
Rashmi R Shah. Br J Clin Pharmacol 2002
151
16

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.
R R Shah, N S Oates, J R Idle, R L Smith, J D Lockhart. Br Med J (Clin Res Ed) 1982
194
16

Studies on the metabolism of perhexiline in man.
R G Cooper, D A Evans, A H Price. Eur J Clin Pharmacol 1987
24
16


Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.
Takashi Nozawa, Shigeki Sugiura, Miki Nakajima, Akihiko Goto, Tsuyoshi Yokoi, Jun-Ichi Nezu, Akira Tsuji, Ikumi Tamai. Drug Metab Dispos 2004
76
16

Concomitant use of antipsychotics and drugs that may prolong the QT interval.
Catherine M Roe, Kevin W Odell, Rochelle R Henderson. J Clin Psychopharmacol 2003
29
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.